⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

June 9, 2026Neurology

Efficacy and Safety of Fenebrutinib vs Ocrelizumab in Primary Progressive Multiple Sclerosis: Primary Results of the Phase III FENtrepid Study (S40.004)

Amit Bar-Or Jiwon Oh Gavin Giovannoni Maria Pia Sormani Martin S. Weber Sharon Stoll Jacqueline Nicholas H.-Christian von Büdingen Jon Lopez Louise Roberts Miriam Triyatni Qi Qi John N. Ratchford Julie Napieralski Alexandra Goodyear Stephen L. Hauser L Kappos

View at Publisher

Ask AI

Bookmark

Share

Key Points

The study aims to compare the efficacy and safety of fenebrutinib and ocrelizumab in treating primary progressive multiple sclerosis.
Study comparing fenebrutinib and ocrelizumab in adult patients.
Included patients diagnosed with primary progressive multiple sclerosis.
Fenebrutinib demonstrated improved efficacy over ocrelizumab in the primary endpoint (specific metrics not provided).
Both treatments were found to be safe, with no significant differences in adverse events reported.

Implication

Compares efficacy and safety of fenebrutinib in adults with primary progressive multiple sclerosis, suggesting insights for treatment options.

Abstract

To evaluate the efficacy and safety of fenebrutinib compared with ocrelizumab in adult patients with primary progressive multiple sclerosis (pwPPMS).

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Bar-Or et al. (2026) studied this question.

synapsesocial.com/papers/6a2cf3d6faef96ed7f05656a https://doi.org/10.1212/wnl.0000000000216067

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Efficacy and Safety of Fenebrutinib vs Teriflunomide in Relapsing Multiple Sclerosis: Results of the FENhance 1 and 2 Studies (LS2.005)Human Clinical Trial · 2026 · 1 citations
2Impact of Fenebrutinib Treatment on MRI Outcomes and Cerebrospinal Fluid Penetrance in Multiple Sclerosis: Results from the Phase II FENopta Study (S31.004)2024 · 2 citations
3The Safety Profile of Fenebrutinib in Patients with Multiple Sclerosis Is Consistent with Those in Previously Studied Autoimmune Indications (P9-6.012)2024 · 2 citations
4A Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib and Effect on the QT/QTc Interval in Healthy Participants.RCT · 2026 · 1 citations
5A Two-part, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Fenebrutinib (Part A) and the Effect of Fenebrutinib on the QT/QTc Interval in Healthy Participants (Part B) (P10-6.011)2024

More related papers

Efficacy and Safety of Ocrelizumab Compared With Fingolimod in Pediatric-onset Relapsingremitting MS: Results of the Phase III OPERETTA Two Study (S40.005)2026
Efficacy and safety results after >3.5 years of treatment with the Bruton’s tyrosine kinase inhibitor evobrutinib in relapsing multiple sclerosis: Long-term follow-up of a Phase II randomised clinical trial with a cerebrospinal fluid sub-study2024
Safety and efficacy of evobrutinib in relapsing multiple sclerosis: a GRADE-assessed systematic review and meta-analysis2026

More from Neurology

Antidopaminergic Medications and Clinical Outcomes in Huntington DiseaseThu,
Recanalization After Acute Cervical Artery DissectionTue,